28th Jul 2015 10:42
LONDON (Alliance News) - OptiBiotix Health PLC Tuesday said that clinical studies on its capsular food supplement to reduce cholesterol are now complete.
The life sciences company has said the aim of the study, which was conducted at the University of Reading, England, was to establish the the ability of its product to lower cholesterol in a group of 50 people.
"We are pleased that we are able to announce the completion of clinical studies on our capsular food supplement with no safety or compliance concerns raised. Volunteer samples will now be tested and the results subjected to statistical analysis to determine the potential of our cholesterol lowering product," Chief Executive Stephen O'Hara said in a statement.
Shares in the company were up 4.0% at 39.37 pence on Tuesday morning in London.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health